Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 405

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial

Open access
Rosenzwajg, Michelle, Lorenzon, Roberta, Cacoub, Patrice, Pham, Hang Phuong, Pitoiset, Fabien, El Soufi, Karim, RIbet, Claire, Bernard, Claude, Aractingi, Selim, Banneville, Beatrice, Beaugerie, Laurent, Berenbaum, Francis, Champey, Julien, Chazouilleres, Olivier, Corpechot, Christophe, Fautrel, Bruno, Mekinian, Arsène, Regnier, Elodie, Saadoun, David, Salem, Joe-Elie, Sellam, Jérémie, Seksik, Philippe, Daguenel-Nguyen, Anne, Doppler, Valérie, Mariau, Jéremie, Vicaut, Eric, Klatzmann, David·2019·Annals of the Rheumatic Diseases

Abstract

OBJECTIVE: Regulatory T cells (Tregs) prevent autoimmunity and control inflammation. Consequently, any autoimmune or inflammatory disease reveals a Treg insufficiency. As low-dose interleukin-2 (ld-IL2) expands and activates Tregs, it has a broad therapeutic potential. AIM: We aimed to assess this potential and select diseases for further clinical development by cross-investigating the effects of ld-IL2 in a single clinical trial treating patients with 1 of 11 autoimmune diseases. METHODS: We performed a prospective, open-label, phase I-IIa study in 46 patients with a mild to moderate form of either rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, psoriasis, Behcet's disease, granulomatosis with polyangiitis, Takayasu's disease, Crohn's disease, ulcerative colitis, autoimmune hepatitis and sclerosing cholangitis. They all received ld-IL2 (1 million IU/day) for 5 days, followed by fortnightly injections for 6 months. Patients were evaluated by deep immunomonitoring and clinical evaluation. RESULTS: ld-IL2 was well tolerated whatever the disease and the concomitant treatments. Thorough supervised and unsupervised immunomonitoring demonstrated specific Treg expansion and activation in all patients, without effector T cell activation. Indication of potential clinical efficacy was observed. CONCLUSION: The dose of IL-2 and treatment scheme used selectively activate and expand Tregs and are safe across different diseases and concomitant treatments. This and preliminary indications of clinical efficacy should licence the launch of phase II efficacy trial of ld-IL2 in various autoimmune and inflammatory diseases. TRIAL REGISTRATION NUMBER: NCT01988506.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2018-214229

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 405

Metadata

Authors
Rosenzwajg, M., Lorenzon, R., Cacoub, P., Pham, H. P., Pitoiset, F., El Soufi, K., RIbet, C., Bernard, C., Aractingi, S., Banneville, B., Beaugerie, L., Berenbaum, F., Champey, J., Chazouilleres, O., Corpechot, C., Fautrel, B., Mekinian, A., Regnier, E., Saadoun, D., Salem, J.-E., Sellam, J., Seksik, P., Daguenel-Nguyen, A., Doppler, V., Mariau, J., Vicaut, E., & Klatzmann, D.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2019-02
Volume
78
Issue
2
Pages
209-217
ISSN
0003-4967 (ISSN-L)
OpenAlex
W2901041673
Cited by
405
References
28
FWCI
13.17
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. https://app.cochat.ai/papers/10.1136/annrheumdis-2018-214229
The paper
Rosenzwajg, M., Lorenzon, R., Cacoub, P., Pham, H. P., Pitoiset, F., El Soufi, K., RIbet, C., Bernard, C., Aractingi, S., Banneville, B., Beaugerie, L., Berenbaum, F., Champey, J., Chazouilleres, O., Corpechot, C., Fautrel, B., Mekinian, A., Regnier, E., Saadoun, D., . . . Klatzmann, D. (2019). Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2018-214229

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.